Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
China
Guangdong Clifford Hospital, Guangzhou, Guangdong West China Hospital of Sichuan University, Chengdu, Sichuan Taiwan
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City China Medical University Hospital, Taichung